Axsome: Sunosi Meets Primary Endpoint in Daytime Sleepiness Associated with Obstructive Sleep Apnea Trial

 Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint)

Statistically significant patient-reported improvement in cognitive function, as measured by the BC-CCI compared to placebo (p=0.002)

Reduced excessive daytime sleepiness compared to placebo (p=0.004 on ESS)

Activation of human TAAR1 by solriamfetol demonstrated in new pharmacology studies

https://www.marketscreener.com/quote/stock/AXSOME-THERAPEUTICS-INC-24949017/news/Axsome-Therapeutics-Announces-Sunosi-Solriamfetol-Meets-Primary-Endpoint-Demonstrating-Improvemen-41913289/